InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Announces AUD Disorder Indication for Psychedelic Molecule CYB003
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has selected alcohol use disorder (“AUD”) as the initial target indication for its proprietary deuterated psychedelic tryptamine, CYB003. In the announcement, the company noted that its CYB003 new chemical entity (“NCE”) could be an ideal investigational new drug (“IND”) candidate for a future clinical trial focused on AUD after preclinical data has…